# *List of Figures*


| Fig. No. | Description | Page No. |
|---|---|---|
| 2.1 | Various nanosystems used for delivery and targeting of theranostic agents | 9 |
| 2.2 | Graphical representation of the number of publications cited in Scopus database on polymeric nanoparticles during the period of 1996–2010 | 10 |
| 2.3 | Schematic representation of systemic drug absorption from intestinal lumen | 11 |
| 2.4 | Schematic representation of various methods of polymeric nanoparticle preparation. SCF: supercritical fluid technology, C/LR: controlled/living radical | 12 |
| 2.5 | Schematic depiction of dialysis method for nanoparticle preparation | 15 |
| 2.6 | Showing the empirical design of supercritical fluid technique methodology of nanoparticle preparation | 16 |
| 2.7 | Conceptual drawing of atherosclerotic/damaged vessels and polymeric nanocarriers with various targeting mechanisms | 19 |
| 4.1 | Schematic depiction of micelle formation and solubilization of poorly soluble drug with surfactants under mild agitation (magnetic stirring) | 43 |
| 4.2 | Schematic representation of preparation of AERSNs via emulsification solvent evaporation method | 47 |
| 4.3 | Schematic representation of APLNs and ALPNs preparations by nanoprecipitation method | 48 |
| 5.1 | Standard calibration plot of ATR in DW | 62 |
| 5.2 | Standard calibration plot of ATR in phosphate buffer pH 7.4 | 63 |
| 5.3 | Standard calibration plot of ATR in phosphate buffer pH 6.8 | 63 |
| 5.4 | Standard calibration plot of ATR in phosphate buffer pH 4.5 | 64 |
| 5.5 | HPLC chromatograms of ATR (200 ng/ml) spiked in plasma as well as in mobile phase samples | 65 |
| 5.6 | Calibration plots of ATR in mobile phase and in plasma samples at 247 nm wavelength | 65 |
| 5.7 | Depiction of micelle formation | 68 |
| 5.8 | Effect of concentration of SLS on the solubility of ATR in different solutions | 69 |
| 5.9 | Effect of concentration of STC on the solubility of ATR in different solutions | 70 |
| 5.10 | Effect of concentration of CTAB on the solubility of ATR in different solutions | 71 |
| 5.11 | Effect of concentration of Tween 80 on the solubility of ATR in different solutions | 72 |
| 5.12 | Effect of concentration of TPGS on the solubility of ATR in different solutions | 73 |
| 5.13 | Values of molar solubilization ratio ($\chi$) of all four surfactants at different pH | 74 |

| Fig. No. | Description | Page No. |
|---|---|---|
| 5.14 | Values of micelle-water partition coefficient ($P_m$) of all four surfactants at different pH | 75 |
| 5.15 | Values of standard free energy of solubilization ($\Delta G_s^o$) of all four surfactants at different pH | 76 |
| 5.16 | Values of binding constant (K) of all four surfactants at different pH | 76 |
| 5.17 | Three-dimensional response surface plot showing the effect of polymer content, concentration of surfactant, volume of organic phase and homogenization speed on (A & B) Mean diameter particle size and (C & D) Mean entrapment efficiency | 79 |
| 5.18 | FT-IR spectra of (a) ATR, (b) PM of ATR and PLGA, (c) Placebo nanoparticles and (d) Optimized batch of AERSNs | 81 |
| 5.19 | DSC thermograms of (a) ATR, (b) PM of ATR and PLGA, (c) Placebo nanoparticles and (d) Optimized batch of AERSNs | 82 |
| 5.20 | PXRD diffractograms of (a) ATR, (b) PM of ATR and PLGA, (c) Placebo nanoparticles and (d) Optimized batch of AERSNs | 83 |
| 5.21 | (A) AFM image (B) TEM image and (C) TEM diffraction pattern of optimized batch of AERSNs | 84 |
| 5.22 | Representing the *in vitro* drug release profile of optimized batch of AERSNs and drug suspension (DS) in phosphate buffer pH 7.4 | 85 |
| 5.23 | The particle size, entrapment efficiency and polydispersity index (PDI) of optimized AERSNs during stability study of 6 months under different environmental conditions | 86 |
| 5.24 | Gas chromatogram of (a) Standard chloroform (1250 ppm) and internal standard 1-propanol (1000 ppm) in deionized water (b) Aqueous sample of AERSNs with internal standard 1-propanol (1000 ppm) | 87 |
| 5.25 | Pharmacokinetic profiles of AERSNs and drug suspension (DS) | 88 |
| 5.26 | Exhibiting (A) Plasma total cholesterol levels (B) Plasma triglyceride levels (C) Plasma low density lipoprotein-cholesterol ($LDL_C$) levels (D) Plasma high density lipoprotein ($HDL_C$) levels and (E) Plasma glucose levels versus time profile of different treated groups | 91 |
| 5.27 | Depicting (A) Plasma creatinine levels (B) Blood urea nitrogen (BUN) levels (C) Plasma creatinine kinase (CK) levels, (D) Plasma lactate dehydrogenase (LDH) levels and (E) Aspartate amino transferase (AST) levels versus time profile of various treated groups | 92 |
| 5.28 | Histomicrograph of stained liver tissue of various groups (A) Normal control, (B) High fat-diet control (C) Placebo nanopaticle treated, (D) Drug suspension treated and (E) AERSNs treated | 94 |
| 5.29 | Three-dimensional surface response plot showing the effect of polymer content, surfactant concentration, volume of organic solvent and stirring speed on (A & B) Mean diameter PS and (C & D) Mean EE of APLNs | 97 |
| 5.30 | FT-IR spectra of (a) ATR, (b) Placebo nanoparticles, (c) Physical mixture of ATR and PLGA and (d) Optimized formulation APLNs | 99 |

| Fig. No. | Description | Page No. |
|---|---|---|
| 5.31 | DSC thermograms of (a) ATR, (b) Placebo nanoparticles, (c) Physical mixture of ATR and PLGA and (d) Optimized formulation batch APLNs | 100 |
| 5.32 | PXRD diffractograms of (a) ATR, (b) Placebo nanoparticles, (c) Physical mixture and (d) Optimized batch of APLNs | 100 |
| 5.33 | (a) AFM image, (b) TEM micrograph image and (c) Electron diffusion ring pattern of optimized batch of APLNs | 101 |
| 5.34 | *In vitro* drug release profile of APLNs and drug suspension in phosphate buffer pH 7.4 | 103 |
| 5.35 | The particle size, entrapment efficiency and polydispersity index of optimized APLNs during stability study of 6 months under different environmental conditions | 104 |
| 5.36 | Gas chromatogram of (a) Standard acetone (1000 ppm) and internal standard 1-propanol (1500 ppm) in deionized water (b) Aqueous sample of APLNs with internal standard 1-propanol (1500 ppm) | 104 |
| 5.37 | Pharmacokinetic profiles of APLNs and drug suspension (DS) (vertical bars represent the standard deviation and dose is equivalent to 20 mg/kg of ATR) | 105 |
| 5.38 | (A-F) Showing the plasma (A) Total cholesterol, (B) Triglyceride, (C) HDL cholesterol, (D) LDL cholesterol, (E) Glucose and (F) Atherogenic ratio level time profile of different groups | 108 |
| 5.39 | Depicting (A) Plasma creatinine levels (B) Blood urea nitrogen (BUN) levels (C) Plasma creatinine kinase (CK) levels, (D) Plasma lactate dehydrogenase (LDH) levels and (E) Aspartate amino transferase (AST) levels versus time profile of various treated groups | 109 |
| 5.40 | Histomicrographs of stained liver tissue of (A) NDC, (B) HFC (C) HFPPLT, (D) HFAST and (E) HFAPT groups | 111 |
| 5.41 | Three-dimensional surface response plot showing the effect of polymer content, surfactant concentration, volume of organic solvent and stirring speed on (A & B) Mean diameter particle size, and (C & D) Mean entrapment efficiency of PNs | 113 |
| 5.42 | FT-IR spectra of (a) ATR, (b) Physical mixture, (c) Placebo nanoparticles and (d) Optimized formulation ALPNs | 114 |
| 5.43 | DSC spectra of (a) ATR, (b) Physical mixture, (c) Placebo nanoparticles and (d) Optimized formulation ALPNs | 115 |
| 5.44 | PXRD diffractograms of (a) ATR, (b) Physical mixture, (c) Placebo nanoparticles and (d) Optimized formulation ALPNs | 116 |
| 5.45 | (A) AFM image, (B) TEM image and (C) Electron diffusion ring pattern of optimized batch of APLNs | 117 |
| 5.46 | Representing the *in vitro* drug release profile of optimized batch of APLNs and drug suspension in phosphate buffer pH 7.4 | 118 |
| 5.47 | The particle size, entrapment efficiency and polydispersity index (PDI) of optimized ALPNs during stability study of 6 months under different environmental conditions | 119 |

| Fig. No. | Description | Page No. |
|---|---|---|
| 5.48 | Gas chromatogram of (a) Standard acetone (1000 ppm) and internal standard 1-propanol (1500 ppm) in deionized water (b) Aqueous sample of ALPNs with internal standard 1-propanol (1500 ppm) | 119 |
| 5.49 | Pharmacokinetic profile of ALPNs and drug suspension (DS) (vertical bars represent the standard deviation and dose is equivalent to 20 mg/kg of ATR) | 120 |
| 5.50 | (A-F) Showing the plasma (A) Total cholesterol, (B) Triglyceride, (C) HDL cholesterol, (D) LDL cholesterol, (E) Glucose and (F) Atherogenic ratio level time profile of different groups | 123 |
| 5.51 | Showing plasma (A) Creatinine levels (B) Blood urea nitrogen (BUN) levels (C) Creatinine kinase (CK) levels, (D) Plasma lactate dehydrogenase (LDH) levels and (E) Aspartate amino transferase (AST) levels versus time profile in different groups | 126 |
| 5.52 | Histomicrograph of stained liver tissue of (A) Normal diet control, (B) High fat-diet control (C) Placebo nanopaticle treated, (D) ATR suspension treated and (E) ALPNs treated groups | 127 |